文献速递肾移植

早期给予抗SARS-CoV-2单克隆抗体可预防肾移植患者的重症COVID-19

Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients.
PubMed 文献 · Kidney Int Rep · 2022-03-26

这项法国全国性研究比较了接受早期抗SARS-CoV-2单克隆抗体输注的肾移植受者与未接受者的COVID-19相关住院、30天ICU入住和30天死亡。80例接受单克隆抗体者与155例倾向评分匹配的对照相比,上述结局发生率均更低。

要点

  • 肾移植受者接受早期单克隆抗体后COVID-19相关住院率为35.0%,对照组为49.7%(P=0.032)。
  • 单克隆抗体组30天ICU入住率为2.5%,对照组为15.5%(P=0.002)。
  • 单克隆抗体组30天死亡率为1.25%,对照组为11.6%(P=0.005),预防1例死亡需治疗人数为9.7。

核心结论

  • 在轻型COVID-19的肾移植受者中早期使用单克隆抗体大幅改善了结局。

研究设计与样本

  • 法国全国性研究,比较接受早期单克隆抗体输注的肾移植受者(单克隆抗体组)与未接受者(对照组)。
  • 对照组来自COVID-SFT登记(NCT04360707),采用倾向评分匹配,协变量包括年龄、性别、移植至感染间隔、诱导和维持免疫抑制治疗、初始症状及合并症。
  • 2021年2月至2021年6月期间共80例肾移植受者接受单克隆抗体,匹配155例对照。

主要发现

  • COVID-19相关住院在单克隆抗体组为35.0%,对照组为49.7%(P=0.032)。
  • 30天ICU入住率在单克隆抗体组为2.5%,对照组为15.5%(P=0.002)。
  • 30天死亡率在单克隆抗体组为1.25%,对照组为11.6%(P=0.005)。
  • 单克隆抗体组无患者需要机械通气。
  • 预防1例死亡需治疗人数为9.7。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Kidney transplant recipients (KTRs) are prone to develop severe COVID-19 and are less well protected by vaccine than immunocompetent subjects. Thus, the use of neutralizing anti-SARS-CoV-2 monoclonal antibody (MoAb) to confer a passive immunity appears attractive in KTRs. METHODS: We performed a French nationwide study to compare COVID-19-related hospitalization, 30-day admission to intensive care unit (ICU), and 30-day death between KTRs who received an early infusion of MoAb (MoAb group) and KTRs who did not (control group). Controls were identified from the COVID-SFT registry (NCT04360707) using a propensity score matching with the following covariates: age, sex, delay between transplantation and infection, induction and maintenance immunosuppressive therapy, initial symptoms, and comorbidities. RESULTS: A total of 80 KTRs received MoAb between February 2021 and June 2021. They were matched to 155 controls. COVID-19-related hospitalization, 30-day admission to ICU, and 30-day death were less frequently observed in the MoAb group (35.0% vs. 49.7%, P = 0.032; 2.5% vs. 15.5%, P = 0.002; 1.25% vs. 11.6%, P = 0.005, respectively). No patient required mechanical ventilation in the MoAb group. The number of patients to treat to prevent 1 death was 9.7. CONCLUSION: The early use of MoAb in KTRs with a mild form of COVID-19 largely improved outcomes in KTRs.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Gueguen J, Colosio C, Del Bello A, et al. Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients. Kidney Int Rep. 2022. PMID: 35372734. doi:10.1016/j.ekir.2022.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。